The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
LettersFull Access

Arrhythmia and Antipsychotic Medications

To the Editor: In a review in the May issue of the cardiac effects of antipsychotic medications (1), among the risk factors for QT prolongation mentioned by Dr. Fayek and his colleagues was the inhibition of the cytochrome P-450 enzyme system by concomitant medications. Of these enzymes, CYP2D6 is particularly important, because a number of antipsychotic agents, including thioridazine, are its substrates.

Not only may the enzymes' activity be inhibited by other medications, but there is also genetic polymorphism for this enzyme, which confers different metabolizer status. Persons with normal rates of metabolism are classified as "extensive metabolizers," and those with lower rates are referred to as "poor metabolizers." In the case of CYP2D6, the proportion of poor metabolizers ranges from 5 to 10 percent among Caucasians, compared with less than 1 percent among Asians (2). Poor metabolizers not only are missing the hepatic component of CYP2D6-mediated metabolism but also lack right ventricular CYP2D6 expression (3). Thus compromised presystemic and target tissue metabolism of most antipsychotic medications in these patients may render them more vulnerable to the cardiotoxic effects of some of these drugs.

Extensive metabolizers who are Chinese tend to have slightly slower metabolic rates than Caucasian extensive metabolizers because of the presence of a special allele (4). Therefore these individuals may be more susceptible to the adverse effects of psychotropic drugs. The presence of this genetic vulnerability has led to the proposal of pharmacogenotyping patients before antipsychotic medications are prescribed (3).

In addition to the risk factors that Dr. Fayek and his associates have highlighted, the presence of stress and extremes of emotion or physical exertion, such as those associated with the use of restraints, may also predispose a patient to arrhythmia (5).

The authors are affiliated with the Institute of Mental Health and with Woodbridge Hospital in Singapore.

References

1. Fayek M, Kingsbury SJ, Zada J, et al: Cardiac effects of antipsychotic medications. Psychiatric Services 52:607-609, 2001LinkGoogle Scholar

2. Glue P, Banfield C: Psychiatry, psychopharmacology, and P-450s. Human Psychopharmacology 11:97-114, 1996CrossrefGoogle Scholar

3. Idle RJ: The heart of psychotropic drug therapy [letter]. Lancet 355:1445, 2000Google Scholar

4. Yue QY, Svensson JO, Alm C, et al: Interindividual and interethnic differences in the demethylation and glucuronidation of codeine. British Journal of Clinical Pharmacology 28:629-37, 1989Crossref, MedlineGoogle Scholar

5. Royal College of Psychiatrists: The Association Between Antipsychotic Drugs and Sudden Death. Council Report CR57. London, Royal College of Psychiatrists, 1997Google Scholar